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For a long time, the human lower airways were considered a sterile environment where the presence of
microorganisms, typically revealed by culturing, was interpreted as an abnormal health state. More recently,
high-throughput sequencing-based studies have led to a shift in this perception towards the notion that
even in healthy conditions the lower airways show either transient presence or even permanent colonization
by microorganisms. However, challenges related to low biomass and contamination in samples still remain,
and the composition, structure and dynamics of such putative microbial communities are unclear. Here, we
review the evidence for the presence of microbial communities in the human lower airways, in healthy subjects and
within the context of medical conditions of interest. We also provide an overview of the methodology pertinent to
high-throughput sequencing studies, specifically those based on amplicon sequencing, including a discussion of good
practices and common pitfalls.Introduction
The human body harbours a varied, complex, and
dynamic community of microorganisms known as the
human microbiome. The term “microbiome” was origin-
ally coined by Joshua Lederberg [1]. Lederberg was spe-
cifically referring to the human microbiome, but since
then the term has been extended to other environments
as well. The original definition does not explicitly state
whether the physicochemical characteristics of the envir-
onment in question are to be included, although not
including them would make “microbiome” synonymous
with “microbiota”. We prefer to make an explicit distinc-
tion that takes into account the ecological concept of
“biome”. Therefore, the human microbiome consists of
bacteria, archaea, protists, fungi, their respective viruses,
and human viruses, as well as the surrounding host
environment in which they exist. In practice, the terms
are often used interchangeably, including in the present
paper, but the meaning is nevertheless readily under-
stood from context.
It has been estimated that the number of bacterial
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of these resident organisms live in a state of commensal-
ism with their human host, making out a living from the
refuse of the host and/or from the metabolic by-products
of other microbes, while others are part of a mutualistic
relationship, in which both host and microbe benefit.
Opportunistic pathogens are microorganisms that are
commonly present in healthy individuals in low levels and
that may become problematic due to abnormal outgrowth
promoted by microbial community disruption and/or due
to a compromised immune system.
Culture-independent methods have enabled the detec-
tion of bacteria in some rather unexpected niches in the
human body. The lower respiratory tract of healthy indi-
viduals has been considered a sterile environment where
the presence of any bacteria, typically revealed by cultur-
ing, represents an abnormal, unhealthy state [4, 5]. As
with many other environments, this may have been
caused by the fact that the microbes present are difficult
to culture under standard laboratory conditions. Re-
cently, numerous studies, particularly those based on
high-throughput sequencing of the gene coding for the
16S ribosomal RNA, have provided tantalizing evidence
that bacteria may be present in the lower respiratory
tract even in healthy subjects. There are challenges in
such studies, particularly related to the low biomass of
the starting material and contamination of the samplesle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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umenting the microbiome in healthy airways and in rela-
tion to medical conditions such as cystic fibrosis [8, 9],
chronic obstructive pulmonary disease [10], asthma [11]
and lung transplantation [12]. In some medical conditions,
the sequencing data is supported by evidence from cultur-
ing methods [13, 14], but many studies rely entirely on a
culture-independent approach.
Here, we provide an overview of DNA sequencing-
based methodology and the microbiome of the human
lower airways, mainly focusing on bacteria, from a 16S
rRNA marker gene high-throughput amplicon sequen-
cing perspective. The reasons for this taxonomic and
technical focus are mostly practical, and include: 1) the
vast majority of published studies deal specifically with
bacteria; 2) phylogenetic marker gene studies that take
into account other taxa require their own specific
primers and downstream processing, increasing the cost
and duration of the studies; 3) lack of standardized pro-
tocols and easy implementation and analysis; 4) less is
known about other taxonomic groups within a human
microbiome context, leading to weaker theoretical evi-
dence from which to derive mechanistic hypotheses
regarding relationships with the human host; 5) many of
those groups have somewhat less relevance to human
disease when compared to bacteria; and 6) shotgun meta-
genomics is significantly more expensive and requires
much more complex and time-consuming analysis.
A brief overview of methods in microbiome
studies
Next generation sequencing in microbial ecology
Next generation sequencing technologies have been
widely applied in microbial ecology research. The most
utilized approaches include shotgun metagenomics and
amplicon sequencing. The term metagenomics was first
used by Handelsman and colleagues [15], and it denotes
examining the structure and function of the entire
(microbial) community based on data derived from bulk
genetic material extracted directly from samples. There-
fore, the produced sequence data contains a fragmented
puzzle of genomes of bacteria, archaea, viruses, fungi,
protists, and even plants and animals, depending on the
studied environment [16].
The first large-scale metagenomics study was con-
ducted by Venter and colleagues in the Sargasso Sea
[17]. They showed that by applying whole-genome shot-
gun sequencing to microbial populations it is possible to
assess the diversity and community structure, and to
discover and at least partially reconstruct previously
unknown microbial genomes. Their results showed that
a considerable share of the detected bacteria were indeed
unfamiliar and resistant to cultivation by common
laboratory methods, and therefore emphasized theimportance of DNA-based techniques in studying di-
verse and still largely unknown microbial populations.
Amplicon sequencing can be defined as a targeted
version of metagenomics: a specific genetic region shared
by the community members of interest is amplified using
universal primers. The produced fragments of similar
length are then sequenced. Amplification success is as-
sumed equal across taxa, and hence each sequence read
randomly represents the genetic diversity in the studied
sample. Typically, the amplified fragment is part of a phylo-
genetically or functionally informative gene, such as the
16S ribosomal RNA gene or other marker genes [18–20].
Therefore, 16S rRNA amplicon sequencing is, strictly
speaking, not metagenomics, although it is common to
describe it as such. The choice of which variable region or
regions of the 16S rRNA gene to target for sequencing is
not trivial, since it affects what taxa are recovered and how
accurately they can be classified [21, 22].
Human microbiome studies are a branch of microbial
ecology. The goal is to study the variation of microbial
communities in regard to, for example, population,
genotype, age, nutrition, medication, biotic and abiotic
environment, and/or its influence on disease. Figure 1
summarizes the typical workflow of an amplicon-based
microbiome study. The first step in any such project is
study design, where many details such as selection
criteria for subjects, type of samples collected, and the
methods used in laboratory and data analysis must be
considered. Sample collection has its specific challenges,
such as avoiding contamination. Once the samples have
been obtained, the laboratory workflow includes DNA
extraction, PCR amplification, purification, and sequen-
cing. For sequencing, there are several different platforms,
each with their pros and cons. The resulting sequence
data is analysed bioinformatically, and finally, compared
with statistical tools. All these steps and their potential
obstacles will be briefly reviewed below. For further
discussion on conducting a microbiome study, see [23].
Sampling and sample processing
Sampling of the lower airways is typically based on bron-
choalveolar lavage (BAL) or collection of induced sputum
(Table 1). Contamination of samples taken from low bio-
mass environments is a pervasive problem in DNA
sequence-based studies [7]. It can occur during sample col-
lection and/or during sample processing at the pre-
sequencing stage. Completely aseptic methods of sample
collection, storage, and processing are a practical impossi-
bility, but the risk of contamination-derived problems is ex-
acerbated when the biomass of the targeted microbiota is
low [24]. This is often the case in human microbiome stud-
ies that rely on samples where few microbes are present,
such as skin swabs or BAL fluid. The lower the microbial
















Fig. 1 General workflow of a microbiome study, from design to data analysis. This schematic is specific for target gene sequencing-based studies
(e.g. 16S rRNA gene) and is not representative of studies using other approaches, e.g. shotgun metagenomics studies
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taminants will swamp the real signal being sought. Potential
sources of contamination include swabs, biopsy needles,
collector, storage and reaction vessels, carryover by bron-
choscopes, as well as the individual performing the sam-
pling, either by accident or mishandling. To our
knowledge, no thorough, systematic studies have beenconducted to evaluate the potential for contamination in
these particular cases.
Contamination issues are not confined to sample
collection; the problem is present in sample preparation at
all stages. Different DNA extraction kits have been shown
to contain different bacterial taxa as contaminants ([7],
unpublished personal observations). Even different lots
Table 1 Next generation 16S rRNA gene amplicon based sequencing studies of the lower airway microbiome









[108] arsenic exposure 10 + 10 sputum IonTorrent V6 QIIME
[91] asthma 10 + 10 sputum 454 V6 RDP
[92] asthma 39 + 12 BAL 454 V1V2 BARTAB, RDP
[56] CF 23 sputum 454 V1V2 AbundantOTU, Lucy,
mothur, RDP
[59] CF 10 lung explant secretions,
sputum
454 V1V3, V2V3 KrakenBLAST, QIIME
[57] CF 17 sputum 454 V4V6 custom in-house pipeline
[60] CF 25 sputum 454 V1V3 RDP
[58] CF 23 sputum 454 V6V7 QIIME
[109] CF 19 + 6 sputum, lung tissue 454 V4V5 Matlab, mothur, RDP
[110] CF 21 sputum 454 V1V2 BARTAB, RDP
[111] CF 30 sputum 454 V1V3 custom software, Kraken
BLAST
[68] COPD 11 sputum MiSeq V4 QIIME
[42] COPD, smoking 19 + 3 BAL, lung tissue 454 V1V3 mothur, RDP
[66] COPD, smoking 16 + 16 lung tissue 454 V1V3 mothur
[41] healthy 6 BAL, lower airway
protected brush
454 V1V2 QIIME
[49] healthy 28 BAL 454 V3V5 mothur
[44] healthy smokers 19 + 45 BAL 454 V1V3, V3V5 mothur
[52] HIV 82 + 77 BAL 454 V1V3 QIIME
[107] ILD 24 + 9 BAL 454 V3V5 PyroTagger
[6] intubation 5 ETA 454 V1V3 MG-RAST, mothur
[104] IPF 55 BAL 454 V3V5 mothur
[105] IPF 65 + 44 BAL 454 V3V5 QIIME
[96] lung transplantation 4 + 2 BAL 454 V3 mothur, RDP
[95] lung transplantation 21 BAL 454 V1V2 QIIME
[12] lung transplantation 33 + 26 BAL 454 V3V5 mothur
[97] lung transplantation 57 + 8 BAL 454 V7V8 QIIME
[102] non-CF bronchiectasis 41 BAL, sputum 454 V1V3 custom software, Kraken
BLAST
[103] non-CF bronchiectasis 42 sputum 454 V1V3 custom software, Kraken
BLAST




20 + 9 BAL 454 V1V2 QIIME
[106] tuberculosis 22 + 14 sputum 454 V1V2 QIIME
[43] various 6 BAL 454 V1V2 QIIME
[112] various 56 + 4 BAL, sputum 454 V1V3 mothur
aIn the case of several publications using the same sequence data, only the first one is included
bSoftware for diversity calculation, statistical comparisons etc. is not included. RDP refers to the standalone implementation. If RDP was used via mothur or QIIME,
it is not listed
Of special interest are the data on number of cases and controls, sample type, and 16S rRNA gene regions targeted for sequencing
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of contaminant biomass. Yet another potential source of
contamination are the laboratory reagents, such as
enzymes, lab-grade water, and buffers. Additionally, the
problem can be exacerbated during PCR amplification
itself, in which with increasing PCR cycle number there is
a corresponding increase in the production of contamin-
ant sequences. Although the amount of the targeted
amplicons will also increase and under ideal circum-
stances the proportions between both should be
maintained, there may be biased amplification of the
undesirable sequences depending on the primer sequences
and DNA sequencing technology used (unpublished
personal observations). This is not a significant issue with
high biomass samples (e.g. stool), because the starting
biomass is so high that there is no need for a large number
of PCR cycles, and therefore the potential contaminant
DNA will be suppressed by the real signal.
There are various approaches that can be used to
minimize the effects of contamination and that are easy
to implement in most lab settings. Table 2 summarisesTable 2 Good practices in microbiome studies
Design considerations • The bacterial “universal” primers show bias in
of the 16S rRNA gene in different studies (as s
(e.g. [21, 22])
Sample collection • Make sure that collecting and storage vessels
body contact or air exposure.
DNA extraction • Perform all activities (as long as it is practical
• Samples should be randomized before DNA e
(case vs. control, age, sex, treatment, etc.) are
create artificial differences between groups du
fashion (see [7] for an excellent and clear exam
• Be generous with controls. Every batch of sam
(control) to which no sample material is adde
sequencing as the “real” samples. This serves
and contamination introduced during the ext
• Keep records of which kit lot was used for DN
kit boxes, even if from the same lot.
• Use kits with bead-beating to increase the ch
taxonomic representation biases will be avoid
• Ensure that all samples from the same project
individual step preferably executed by the sam
PCR • When possible, work in a PCR clean room.
• Sequence a PCR master mix “blank” (control)
mix controls serve the purpose of detecting p
introduced during preparation) every time a n
• Use PCR replicates to minimize PCR bias (une
diversity present in samples as thoroughly as
per sample.
Sequencing • If possible, sequence a mock community prep
composition of this community is known, it c
the target samples.
This list is provided as an example of technical considerations that must be taken in
The second and third sections are important for sequence-based studies in general
requiring target DNA amplification prior to sequencingsome of those approaches, as well as other general con-
siderations that are important for effective sample hand-
ling and processing.
There have been suggestions for treating reagents from
extraction kits and PCR mixes using, for example, differ-
ent types of radiation, restriction enzymes, or DNases
[7]. All of these decontamination procedures have
advantages and disadvantages, and their use needs to be
evaluated within the context of the study in mind.
Additionally, sequencing the complete genomes of com-
mon contaminants to identify and computationally sub-
tract them from the data, will in the future help to
distinguish between contaminants and real signal [24].
For a comprehensive review of these issues, as well as
suggestions for dealing with them, see [7] and references
therein.
Sequencing, bioinformatics and data analysis
The majority of published 16S rRNA gene sequencing
based lower airway microbiome studies have used
Roche’s 454 pyrosequencing platform (Table 1). WithPCR amplification of certain taxa, and the use of different regions
een for the lower airways in Table 1) affects inter-study comparisons
are not needlessly subjected to potential contamination either by
to do so) under a hood with air filtering.
xtraction so that batch effects are minimized when groups of interest
compared. Varying contamination in kit lots and laboratory reagents can
ring statistical analysis if the samples are not handled in randomized
ple).
ples being isolated at the same time should include one kit “blank”
d but which undergoes the same process of DNA extraction and
the purpose of controlling for both contamination present in the kit
raction process.
A extraction of which sample, and don’t mix reagents from different
ances that taxa with thicker cell walls will be properly lysed and that
ed as much as possible.
are handled in the same way following a common protocol, each
e person.
for each different master mix aliquot. Do not add any template. Master
otential contamination in PCR reagents (already present or accidentally
ew master mix is prepared.
ven PCR amplification, lack of reaction effectiveness) and to detect the
possible [113]. A minimum of two replicate reactions should be prepared
ared from genomic DNA from known isolates. Since the sequence
an be used to identify contamination effects and sequencing errors in
to account in studies involving DNA sequencing of environmental samples.
, while the first, fourth, and fifth sections are of special interest for studies
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Illumina’s sequencers are quickly becoming the stand-
ard for both amplicon and shotgun metagenomics
studies. The Illumina MiSeq platform in particular
will probably eventually dominate amplicon-based
microbial surveys. The various existing sequencing
platforms have marked differences in read lengths,
throughput, run time, error profiles, and cost
[25, 26].
Regardless of the sequencing platform used, the raw
sequence data requires several quality control steps to
avoid bias and artefacts caused by the PCR amplification
and sequencing [27] Low quality reads are removed
based on criteria such as quality scores, mismatches to
barcodes and primers, sequence length, and the presence
of ambiguous bases. Chimeric reads, which are the result
of PCR products where two or more different template
sequences have accidentally been joined together, are
also removed [27]. After quality control, the sequences
are typically clustered to operational taxonomic units
(OTUs). Clustering can be performed based on only the
sequences themselves (“de novo”), using a reference
database of known sequences as cluster centroids
(“closed-reference OTU picking”), or with a combination
of the two approaches (“open-reference OTU picking”)
[28]. Regardless of the method, clustering is usually
based on a 3% dissimilarity cut-off, which is used as a
proxy for species [29]. It is also possible to omit the
clustering step entirely and to simply use a reference
database to identify each sequence read, binning to-
gether those that have the same taxonomic classification
(“phylotype” approach). All methods that rely on a refer-
ence database are highly dependent on the quality of the
database, while the database-independent “de novo”
approach is computationally heavier than the other alter-
natives. It is particularly important to note what
approach has been used when comparing different stud-
ies, since different clustering methods can produce
widely varying results [30, 31]. After clustering, the
resulting OTUs are identified taxonomically using a suit-
able reference database. This is another step where
different databases may lead to major differences in the
results.
An additional quality control consideration particularly
for studies using low biomass samples is that the data
may include contaminants [7]. The data from samples
should be compared to sequenced negative controls and
to existing publications, to look for unexpected discrep-
ancies that could suggest contamination.
There is a large selection of software available for each
step in the analysis of 16S rRNA gene sequence data,
from quality control to clustering and taxonomical clas-
sification. Instead of using a different tool for each step,
many researchers prefer software packages that coverthe complete workflow from raw sequence data to final
results. The most commonly used ones are mothur [32]
and QIIME [33], and the choice between the two is
more of a question of personal preference, since both
can be used to perform nearly the same tasks. The bio-
informatic workflow should always be documented as
meticulously as the laboratory work, to ascertain that it
is replicable.
The results of the bioinformatic sequence analysis typ-
ically include representative sequences for the OTUs
and a table that summarizes how many sequences of
each OTU are present in each sample. The total amount
of sequences per sample can vary significantly, and it is
important to take this library size variation into account
in statistical comparisons. Traditionally, this has been
done by rarefaction or by converting the counts into
relative abundances, but neither approach is optimal [34],
and there are alternatives, such as the normalization
methods offered by the metagenomeSeq [35] and phylo-
seq [34] R packages. Depending on the study design, the
microbial community data can be used for a wide variety
of statistical tests, which include, but are not limited
to, searching for OTUs that are over or underrepre-
sented in some predefined group (e.g. test subjects
with a specific medical condition), comparisons of
microbial diversity within and between samples or
groups, and multivariate statistics for exploring the
possible associations between clinical data and com-
munity composition. If OTUs of particular interest
are discovered, the sequence data can be used for
further analyses of the OTUs in question, both in
continued bioinformatic and statistical analysis as well
as in future experiments that focus on specific taxa
instead of the entire microbiome.
As an end note, by microbial diversity we mean a
measurement that takes into account both species
richness (number of different taxa) and evenness
(how abundant the taxa are). For any given sample,
this would be represented by alpha diversity using
such indices as Shannon or Inverse Simpson. Beta di-
versity consists of a distance measure between sam-
ples that represents the compositional dissimilarity or
heterogeneity between those same samples. Typically,
the higher the value of the beta diversity index for
any given comparison the higher the dissimilarity be-
tween the samples. Notice that different indices have
different meanings from an ecological point of view,
and their interpretation is not always straightforward.
In this review, we try to avoid ambiguity by identify-
ing the meaning of “diversity” as used by the authors
of specific articles mentioned in the text. For more
information on this topic we suggest the articles by
Jost [36, 37], Tuomisto [38], and Anderson et al. [39],
and references therein.
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The development of DNA-based methods has already
changed our knowledge of the structure and function of
our genome as well as our second, microbial genome.
Although DNA sequencing is going to become even
cheaper in the future, easing the financial constraints on
human microbiome studies, many problems remain that
are related to study design and analysis of the results
rather than just producing data. Bioinformatic tools are
still being developed, and comparing results from report
to report can be challenging due to the lack of consen-
sus in analysis and presentation of data. Since new
methods may require tailor-made analysis, this problem
is likely to remain unsolved in the foreseeable future.
Shotgun metagenome projects, which avoid many of
the limitations of the 16S rRNA gene approach, are gain-
ing in popularity. They require no selected regions, just
brute force sequencing. However, they also add new
obstacles to the data analysis, making it more complex
and significantly heavier computationally. On the other
hand, the results will be more comprehensive and more
to the point as reference databases are being filled with
well annotated genomes and metagenomes. More func-
tional insight can be obtained, especially as more RNA
analyses are performed. Clinical diagnostics will be
driven to sequencing-based approaches in the near fu-
ture. Single-molecule sequencers, such as PacBio and
the upcoming nanopore solutions, will be used to rapidly
evaluate samples from unknown infections. Mass spec-
trometry is developing nearly as fast as DNA sequen-
cing, opening novel opportunities in research and
diagnostics. Still, sampling is the key to success. When
samples are small or of limited quality, contamination
problems will remain serious when these very sensitive
assays are used.
The microbiome in healthy lower airways
The first studies using molecular methods to characterize
the microbiome of the lower airways concluded that while
the lower airways of healthy subjects are not sterile, the
amount of bacteria is low, and the community is mainly
made up of bacterial genera that are also common in the
upper respiratory tract, including Prevotella, Streptococcus
and Veillonella [40–42]. Haemophilus spp. [40] and
Tropheryma whipplei [41] were suggested as bacteria
specific to the lower airways. Later analysis of healthy
subjects from an earlier study [41] suggested that three
out of six subjects had some OTUs that were enriched in
BAL fluid compared to oral wash samples, but all of them
were found to be common in either negative controls or
peri-glottic samples [43].
In more recent publications, several approaches have
been used to eliminate possible contamination and to
define statistically which bacteria are typical of thehealthy lower respiratory tract. One study listed OTUs
classified as Ralstonia, Bosea, Haemophilus, Methylobac-
terium, Tropheryma and an unclassified Enterobacteria-
ceae OTU as potentially lung-specific [44]. Although
samples with communities similar to negative controls
were removed from the analysis, many of the genera on
this list (particularly Ralstonia, Bosea and Methylobac-
terium, as well as Enterobacter, a genus of Enterobacteri-
aceae) correspond to a published list of common
contaminants [7], raising questions regarding their ac-
tual origin. Another fairly recent study suggested two
“pneumotypes”, one of them including genera similar to
“background” or negative control samples, the other
with a community resembling that of supraglottic sam-
ples, with high levels of Prevotella and Veillonella [45].
The negative controls and the samples similar to them
were shown to contain a Streptococcus species different
from the one typically found in supraglottic samples and
supraglottic-like BAL samples. However, it is possible
that the background-like “pneumotype” does not repre-
sent a true bacterial community, especially since the
BAL samples were centrifuged before DNA isolation and
only the supernatant was used, which is likely to have an
impact on the resulting bacterial communities.
When viewed critically, the existing publications that
strive to characterize the microbiome of the healthy
lower respiratory tract are not without problems. Many
of the bacteria common to the upper airways that have
also been detected in the lower airways are likely to
originate from microaspiration (subclinical aspiration of
small droplets) of oropharyngeal secretions (e.g. [46]),
which could mean that their presence is transient. It has
been suggested that there is no lung “core” microbiome
that is similar across study subjects and stable over time,
but that the oral microbiome influences the microbial
content in lungs [47]. Another possible source could be
gastric reflux [48]. Contamination during sampling may
also play a role. On the other hand, recent studies have
shown that the BAL microbiome can be sampled with-
out upper respiratory tract contamination [45] and that
the lung microbes differ significantly from oral and gas-
tric bacterial community [49]. Additionally, it seems that
the sampling route (via nose or mouth) does not signifi-
cantly affect the BAL microbiome [12].
Finally, it is also important to keep in mind that the
standard 16S rRNA gene amplicon sequencing approach
does not differentiate living, active cells from dead ones,
raising the possibility that, at least in part, the recovered
DNA has its origins in non-viable bacteria. Supporting
this view is a study in healthy young pigs in which
DNase was added to porcine BAL fluid and lung tissue
samples [50]. While total bacterial DNA was abundant
in both sample types, treatment with DNase substan-
tially reduced the amount of cultivable cells, and showed
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other hand, Venkataraman et al. [51] showed evidence
that 61% of 16S rRNA gene sequences recovered from
healthy lung BAL could be matched to species recovered
by a diverse assortment of culturing techniques. Of fur-
ther interest, the study supports a neutral model of com-
munity ecology in which most of the bacteria in healthy
(as opposed to diseased) lungs are the result of dispersal
sourced mainly from the oral cavity, with dispersal and
ecological drift dominating over selective forces in shap-
ing healthy lung communities.
Out of the genera suggested to be enriched in the
lower airways, some, such as Haemophilus [40, 44] and
Tropheryma [41, 44, 52], have been reported in multiple
studies, and are not known contaminants [7]. Further re-
search is needed to ascertain whether there truly is a
specific, stable lower airway microbiome in healthy sub-
jects, or if the bacteria that have been discovered from
such subjects are only transient visitors [48].The lower airway microbiome and specific
medical conditions
Cystic fibrosis
Cystic fibrosis (CF) is a recessive genetic disease particu-
larly common in Caucasian populations [53]. It is caused
by mutations that lead to the loss of function or dys-
function of the CF transmembrane conductance regula-
tor protein (CFTR), which among other things causes
abnormal mucous secretions and low airway surface pH,
facilitating bacterial colonization of the lung [8]. Lung
failure associated with chronic airway infections is the
most common cause of morbidity and mortality in CF
[9]. Based on the amount of publications (Table 1), CF is
the lower respiratory tract related condition most com-
monly studied with next generation 16S rRNA gene
sequencing.
CF airway infection is caused by a complex community
of microbes [54], but only a handful of bacterial species
have been established as clinically relevant. Particularly
important pathogens are diverse strains of Pseudomonas
aeruginosa, and the Burkholderia cepacia complex (Bcc)
[8]. Other notable species include Haemophilus influen-
zae and Staphylococcus aureus, both common in paedi-
atric CF patients, and emergent pathogens such as
Stenotrophomonas maltophilia, Achromobacter xylosoxi-
dans, Mycobacterium abscessus and the Streptococcus
milleri group [8, 9]. In addition to recognized pathogens,
many genera typical to the upper airways and to healthy
lower airways, such as Prevotella and Veillonella, are
also present in CF patients’ lower airways [8, 9]. A study
where the taxa found in CF sputum samples were parti-
tioned statistically to satellite and core groups suggested
that the core genera include Porphyromonas, Prevotella,Streptococcus, Catonella, Veillonella, Neisseria and
Pseudomonas [55].
Several studies have shown that the microbiome of the
CF airways is very stable: neither clinical exacerbation
nor antibiotic treatment have a significant effect on the
patients’ microbiota [56, 57]. A recent study reported
that although antibiotic treatment of P. aeruginosa in-
fected CF patients with pulmonary exacerbations initially
caused a drop in the relative abundance of Pseudomonas
and an overall increase in alpha diversity (measured with
the Shannon diversity index), the microbial communities
reverted to their pre-treatment state within 8–10 days of
starting the treatment [58].
A majority of published CF studies have used sputum
samples (Table 1), which are thought to represent the
lower airway microbiota [59]. One study reports that the
communities in sputum and in mouthwash samples are
extremely similar, except for a small number of taxa, but
suggests that this is probably due to microaspiration, re-
ferring to earlier studies as proof that sputum and oral
microbiota are different [56]. However, another study
using secretions obtained from lung explants concludes
that sputum samples are not good surrogates for the
lung microbiome, which is mainly dominated by typical
CF pathogens and less diverse than the upper airway
microbiome [59]. A recently suggested additional source
of lower airway microbiota in CF patients is aspirated
bile, which seems to affect the community composition
significantly [60].
Chronic obstructive pulmonary disease and smoking
Chronic obstructive pulmonary disease (COPD) is a pro-
gressive lung disease that is mainly defined by irrevers-
ible airflow limitation, small airway fibrosis, mucus
hypersecretion, and tissue destruction [61–63]. The lead-
ing cause of COPD in the developed world is exposure
to tobacco smoke, and in developing countries indoor
air problems from biomass fuel combustion also increase
the occurrence [64]. It is not known why some of the ex-
posed develop the disease and others do not, but a mi-
crobial component in the etiology is possible, as the lung
microbiome seems to differ between healthy and affected
individuals [40, 47, 65–67].
Several studies suggest that COPD patients carry bacteria
in their lungs that are not present in healthy individuals.
These bacteria include for example Moraxella, Curvibacter,
Corynebacterium [65], and dominance of Pseudomonas
[42]. However, a general consensus about the significance
of individual taxa and their involvement in the pathogenesis
of COPD is still lacking. Attempts to define the association
between COPD and microbial diversity in the lungs have
given rather contradictory results: it has been suggested
that the COPD lung microbiome is richer [67] and more
diverse (Shannon and inverse Simpson) [47], that there is
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affected lungs [10, 65], and that healthy lungs carry a more
diverse microbiome (non-parametric Shannon) [42]. This
inconclusiveness is probably linked to several factors: the
interpersonal variation between lung microbiota is large
and influenced heavily by the oral microbiome [47]; differ-
ent lung compartments are dominated by different bac-
teria [42, 67]; and different levels of disease severity and
medication affect the microbial community structure and
diversity [47]. For instance, inhaled corticosteroids that
are commonly used to treat COPD and asthma change
the microbiome, advance enrichment of many community
members, and may promote bacterial colonization in the
airways [68]. In addition, the number of study subjects,
sampling, selected laboratory protocols and analysis
methods play a crucial role in the reliability of results.
Regarding smoking, in a recent thorough study com-
prised of sixty-four participants, the authors conclude
that, although the data supports the existence of differ-
ences between the oral microbiome of “healthy” smokers
and non-smokers, this does not seem to be the case
regarding the lung communities, suggesting that the
latter are not significantly altered by smoking [44]. An
earlier study suggests that there is lower bacterial diversity
(non-parametric Shannon) in smokers with moderate to
severe COPD when compared to “healthy” smokers and
non-smokers (the last two groups appearing to have no
significant differences overall) [42]. Other studies have
supported the hypothesis that lung bacterial communities
don’t differ significantly between smokers and “healthy”
smokers, while also adding to the evidence for differences
in patients with severe COPD [45, 66].
Asthma
Asthma is a complex, chronic disorder where
inflammation-related changes in the airways lead to air-
flow limitation, causing recurring symptoms such as
coughing, wheezing and breathlessness [69]. While the
actual causes of asthma remain obscure, work conducted
in recent years has unravelled a possible role for micro-
biota in either promotion of or protection from the
disease [11, 70, 71]. As in other medical conditions
discussed in this review, the data is strongly suggestive of
a distinct pulmonary microbial community in healthy
versus asthmatic people. Several studies suggest associa-
tions between environmental microbial exposure and the
risk of developing asthma [72–75], or a role for antibiotic-
induced gastrointestinal tract community effects during
the first years of life [76–79]. The latter hypothesis is sup-
ported by the concept of a compartmentalized “common
mucosal immune system”, in which microbe-induced
differences in immunity at one mucosal site (e.g. gut) can
affect immune function at other sites, including the muco-
sal surfaces of the airways [80–82].Diverse studies, based on methods such as culturing,
PCR, and/or DNA sequencing, have shown an association
between asthma and certain microbial taxa. Implicated
taxonomic groups include Mycoplasma pneumoniae and/
or Chlamydophila pneumoniae [83–87]; Moraxella catar-
rhalis, Haemophilus influenzae, and/or Streptococcus
pneumoniae [88, 89]; significantly more Proteobacteria,
particularly Haemophilus spp., as well as Staphylococcus
spp., but less Bacteroidetes, especially Prevotella spp. [40];
increased abundance of ~100 bacterial taxa distributed
into 31 families, mostly Proteobacteria [90]; and higher
levels of Proteobacteria, especially Gammaproteobacteria,
in asthma cases [91]. Some studies report higher bacterial
diversity in asthma [90, 91], while one study found no dif-
ference in diversity between controls and asthmatics [92].
Fungi have also been investigated in the context of
asthma, with 90 fungal species showing higher relative
abundance in sputum samples from asthma cases
(particularly Psathyrella candolleana, Malassezia pachy-
dermatis, Termitomyces clypeatus and Grifola sordulenta)
while 46 were more abundant in controls (particularly
Eremothecium sinecaudum, Systenostrema alba, Clados-
porium cladosporioides and Vanderwaltozyma polyspora)
[93]. Malassezia pachydermatis, which has been associ-
ated with atopic dermatitis as well as other atopic condi-
tions, was present in asthma patients but not in the
control group. Viral infections at early ages have also been
associated with asthma [75].
Whether the aforementioned associations represent a
causative or mediating role for microbiota in asthma, or
reflect the result of community disturbances due to
other causes is unclear [71]. A potential confounding
factor that may affect conclusions derived from some of
these studies is the use of patients that are under med-
ical treatment (e.g. [40, 90]) which may produce anomal-
ous microbial communities as a consequence. This is a
potential problem for clinical studies in general, and
extra care and consideration should be given to disen-
tangle the effects of medication (e.g. antibiotics) from
the real signal. A particular confounder in asthma stud-
ies could be the use of inhaled corticosteroids, which are
immunosuppressive and could affect the lower airway
microbiome. However, the results of a study where most
of the asthmatic subjects were not using corticosteroids
[91] were in line with older studies where corticosteroid
use was not controlled for [40, 90]. See also [92, 94].
Other conditions
It has been reported that the bacterial and fungal com-
munities in the lower airways of lung transplant recipi-
ents differ from those of their upper airways, as well as
from the upper and lower airways of healthy subjects
[95, 96]. Although one small study suggests that the
lower airways of transplant recipients have higher
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indices) than those of healthy subjects [96], most studies
have concluded that the diversity is lower in transplant
recipients’ airways (species richness and Shannon index)
[12, 95, 97]. According to one study, the risk of bron-
chiolitis obliterans syndrome (BOS) is higher when the
post-transplantation microbial community is distinct
from the pre-transplantation state, while reestablishment
of the pre-transplantation community has a protective
effect, even when the subjects have CF and the commu-
nity includes the potentially pathogenic Pseudomonas
[97]. In a recent study, lung transplant recipients were
found to have communities dominated by either P. aeru-
ginosa, identified by both culturing and sequencing and
associated with worse clinical status, or by P. fluorescens,
which was only detectable by molecular methods, and
typically found in asymptomatic subjects [12].
Since HIV patients have an increased risk of recurrent
pneumonia, their lower airway microbiome has been
studied, and there is a large multicenter research project,
the Lung HIV Microbiome Project (LHMP), dedicated
to it [44]. A high abundance of Tropheryma whipplei
has been suggested as characteristic to HIV patients
[52]. Antiretroviral therapy appears to have an effect on
the microbiota [52, 98]. A metabolomics study using
liquid chromatography-high-resolution mass spectrom-
etry found that BAL samples from healthy subjects and
HIV-1 infected patients had different metabolite profiles,
and since many metabolites remained unidentified while
one was identified as a siderophore of P. aeruginosa, the
difference might be due to different microbiota [99].
While most of the airway microbiome publications cited
in this review have studied Western populations, a
microarray-based study compared BAL samples from
HIV-infected pneumonia patients in Uganda [100] to an
earlier study of a similar cohort from San Francisco [98],
concluding that the Ugandan population had more diverse
airway microbiota, and that several pathogenesis-
related pathways were enriched in their predicted
metagenome [100].
Several recent publications have addressed non-cystic
fibrosis bronchiectasis. One study suggested that the
complex microbial community present in the patients’
lower airways remains unchanged during exacerbations
[101]. Another study found that community composition
and diversity, particularly species richness, are correlated
with lung function [102], leading to the proposal of a
microbiome-based stratification system for predicting
exacerbations, where patients with high relative abun-
dance of P. aeruginosa or Veillonella are more likely to
suffer frequent exacerbations than those with high abun-
dance of H. influenzae [103].
Recently, an association between the lung microbiome,
idiopathic pulmonary fibrosis (IPF) and diseaseprogression has been identified [104, 105]. IPF is a pro-
gressive lung disease with unknown etiology that leads
to respiratory failure and death typically within three to
five years of diagnosis. It has been shown that patients
with IPF have more than twofold higher pulmonary bac-
terial load compared to healthy individuals, and in-
creased abundances of Haemophilus, Neisseria, and
Veillonella [105]. Furthermore, the disease progression
is associated with increased relative abundances of
Streptococcus and Staphylococcus, and the overall bacter-
ial burden: patients with highest bacterial load had more
rapidly progressing disease, and a substantially in-
creased risk of death [104, 105]. Further research is
needed to determine if the changed microbiome is a
cause or the result of IPF, but the findings provide sup-
port for testing antimicrobial therapy in IPF.
Other conditions that have been studied in relation to
the microbiome of the lower airways so far include
tuberculosis [106], interstitial lung disease [107], arsenic
exposure [108] and intubation [6].
Conclusion
The study of the human lower airway microbiome is still
in its infancy. The research suggests that, contrary to
what was previously thought, the lower airways are
inhabited by a diverse bacterial community. Although
the evidence is not conclusive, it has strong support
from a variety of studies performed throughout the his-
tory of the field, using different and complementary
methods. Regardless of what the true scenario is, there is
little consensus on the actual impact of specific bacterial
taxa, or of the community structure and diversity on hu-
man health and disease. At present, published studies
suggest that healthy and affected (e.g. CF, COPD,
asthma) lungs carry partly distinct bacterial communi-
ties. Still, it is not known whether this difference is a
cause or a consequence of the disease, and whether the
varying bacterial communities reflect the disease sever-
ity, or if it is actually the medication that alters the com-
munity structure. As for healthy lung communities, it is
at present not possible to differentiate between a mu-
tualistic role for bacteria in promoting health as opposed
to an essentially neutral, purely commensal role. Add-
itionally, the amounts of study subjects in published pa-
pers are relatively small, the used methods rather
dissimilar, and the differences between studies also sug-
gest broad interindividual variation. More controlled
studies are needed to solve the role of the lower airway
microbiome in health and disease. Based on current
data, larger study cohorts, standardised sampling proto-
cols and laboratory procedures to avoid any misinter-
pretation caused by contamination, as well as carefully
selected sequencing and detection methods are essential
in future projects.
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